Dine Brands (NYSE:DIN) Exceeds Q2 CY2026 Expectations

Dine Brands (NYSE:DIN) reported Q2 CY2026 results. Revenue rose 4.4% year on year to $240.9 million, beating market expectations by 1.7%, according to the company. Non-GAAP EPS was $1.16, 3.3% below analysts’ consensus. Same-store sales fell 1.8% y/y. The stock rose 3.6% to $36.10 after the report.

Original reporting
Published Aug 5, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 1:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dine Brands (NYSE:DIN) Exceeds Q2 CY2026 Expectations — source image
Decision brief

The 30-second read

$DINNeutralMed
01

Why it matters

The article frames Q2 as mixed: revenue beat and modest YoY growth, but same-store sales declined and EBITDA missed, which can influence valuation and near-term expectations.

02

Market read

Traders can reassess near-term fundamentals after the Q2 print, balancing the revenue beat against weakening same-store sales and EBITDA underperformance.

03

What to watch

Restaurant count stayed flat, so investors may focus on whether operational efficiency can offset traffic softness and whether EBITDA weakness persists next quarter.

Relevance 6/10Novelty 5/10Timing: immediately after Q2 CY2026 results, with stock up 3.6% to $36.10

Background

Dine Brands runs a franchise model and operates Applebee’s and IHOP, with performance often hinging on same-store sales and unit growth decisions.

Company-level read

Ticker impact

$DINNeutralMedium confidence
Context

Dine Brands reported Q2 CY2026 revenue of $240.9M, up 4.4% YoY, beating expectations, and shares jumped 3.6% to $36.10.

Expected impact

Short-term upside bias from the revenue beat, but follow-through may be capped by -1.8% same-store sales and EBITDA miss.

Evidence & confidence

The article provides concrete results (revenue beat, EPS figure, same-store sales down, EBITDA missed) plus an immediate post-report stock move, which together frame a mixed but tradable reaction.

Market effects

Signals modest demand pressure in casual dining via same-store sales weakness, despite top-line resilience.

No regional-specific information provided.

No global macro or cross-border demand drivers mentioned.

Counterpoint

The revenue beat may reflect timing or mix rather than improving traffic, since same-store sales fell 1.8% YoY and demand has been declining for two years.

Key entities

  • Dine Brands

    Reported Q2 CY2026 results with revenue beat, EPS miss vs consensus, same-store sales decline, and a same-day stock pop.

Related articles

$DINMed

Dine Brands (DIN) Q2 2026 Earnings Call Transcript

Dine Brands Global (DIN) reported Q2 2026 revenue of $240.9 million, up 4.4% year over year, driven mainly by acquiring restaurants from franchisees. Adjusted EBITDA fell to $54.2 million and adjusted diluted EPS was $1.16. IHOP domestic comps rose 1.5%, Applebee’s fell 1.8%. Management maintained full-year 2026 guidance.

$DINMed

Dine Brands Global, Inc. Q2 2026 Earnings Call Summary

Dine Brands Global (Applebee’s, IHOP) reported Q2 2026 call updates: management cited intentional consumer spending amid inflation and maintained full-year guidance. Applebee’s saw sequential improvement after a weak April, with remodels lifting mid-single-digit sales. IHOP beat traffic benchmarks for a third quarter. Adjusted FCF fell to $3.7M in H1; $100M buyback authorized.

$DINMed

Dine Brands Global, Inc. (DIN): Results of Operations and Financial Condition

Dine Brands Global, Inc. (DIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d148591dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 News Release Investor Contact Matt Lee Sr. Vice President, Finance and Investor Relations Dine Brands Global, Inc. IR@dinebrands.com Media Contact Susan Nelson Sr. Vice President, Global Communications Dine Brands Global, I

$ORGOMed

Organogenesis (ORGO) Q2 2026 Earnings Call Transcript

Organogenesis (ORGO) reported Q2 2026 revenue down 58% year over year, driven by a 61% drop in Advanced Wound Care sales. Net product revenue rose 18% quarter over quarter. The company cited CMS coverage changes as slowing recovery, announced a June restructuring with 138 job cuts and about $18M annualized cost savings, and updated 2026 revenue guidance. It also cited DFU and venous ulcer study results and FDA acceptance of Amnuvx BLA with a PDUFA date of Apr 24, 2027.

$CRWVMed

CoreWeave Stock Buy or Sell Debate Intensifies in 2026 After Q2 Beat and $104 Billion Backlog

CoreWeave Inc. shares closed at $105.26 on Aug. 14, 2026 after its Q2 results. Revenue rose to $2.58B from $1.21B a year earlier; adjusted operating income was $128M, but GAAP net loss widened to $626M due to higher interest expense. The company raised 2026 revenue guidance to $12.4B-$13.2B and projected adjusted operating income of $960M-$1.15B. Backlog was about $104B.

$CELCMed

Celcuity Q2 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.